Low within-and between-day variability in exposure to new insulin glargine 300 U/ml

被引：0
|
作者：
Becker, R. H. [1 ]
Nowotny, I. [1 ]
Teichert, L. [1 ]
Bergmann, K. [1 ]
Kapitza, C. [2 ]
机构：
[1] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
[2] Profil, Neuss, Germany
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
953
引用
收藏
页码：S390 / S390
页数：1
相关论文
共 50 条
  • [1] Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
    Becker, R. H. A.
    Nowotny, I.
    Teichert, L.
    Bergmann, K.
    Kapitza, C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (03): : 261 - 267
  • [2] Low Within- and Between-Day Variability in Exposure to New Insulin Glargine 300 U.mL-1
    Becker, Reinhard H. A.
    Nowotny, Irene
    Teichert, Lenore
    Berg-Mann, Karin
    Kapitza, Christoph
    DIABETES, 2014, 63 : A228 - A228
  • [3] Day-to-day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
    Miller, Michelle
    Pires, Jully
    Crakes, Katti
    Greathouse, Rachel
    Quach, Nina
    Gilor, Chen
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2021, 35 (05) : 2131 - 2139
  • [4] Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats
    Saini, N. K.
    Wasik, B.
    Pires, J.
    Leale, D. M.
    Quach, N.
    Culp, W. T. N.
    Samms, R. J.
    Johnson, A. E.
    Owens, J. G.
    Gilor, C.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 75
  • [5] Lower pharmacokinetic and pharmacodynamic within-day variability of individual clinical doses of insulin glargine 300 U/ml vs glargine 100 U/ml in type 1 diabetes
    Fanelli, C. G.
    Lucidi, P.
    Candeloro, P.
    Cioli, P.
    Andreoli, A. Marinelli
    Bolli, G. B.
    Porcellati, F.
    DIABETOLOGIA, 2018, 61 : S409 - S409
  • [6] Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    Steinstraesser, A.
    Schmidt, R.
    Bergmann, K.
    Dahmen, R.
    Becker, R. H. A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (09): : 873 - 876
  • [7] Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
    Heise, Tim
    Norskov, Marianne
    Nosek, Leszek
    Kaplan, Kadriye
    Famulla, Susanne
    Haahr, Hanne L.
    DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1032 - 1039
  • [8] Lower Pharmacokinetic and Pharmacodynamic Within-Day Variability of Individual Clinical Doses of Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in T1DM
    Fanelli, Carmine
    Lucidi, Paola
    Candeloro, Paola
    Cioli, Patrizia
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Porcellati, Francesca
    DIABETES, 2018, 67
  • [9] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
  • [10] Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?
    Heise, Tim
    Heckermann, Sascha
    DeVries, J. Hans
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2051 - 2056
12345